Company: PFSA
Filing Date: 2025-02-12
Form Type: S-4/A
Source: 0001213900-25-012354
Chunk: 30

Company: Profusa, Inc.
Filing Date: 2025-02-12
Form: S-4/A
Chunk 30
---
 in connection with a shareholder meeting on March21, 2024, related to the extension of NorthView’s business combination period monthly, for up to six months, from March22, 2024, ultimately until as late as September22, 2024. On September19, 2024, the NorthView stockholders elected to redeem 50,556 public shares of NorthView Common Stock in connection with the extension of NorthView’s business combination period monthly, for up to six months, from September22, 2024, ultimately until as late as March22, 2025. At the time of the stockholder vote on September19, 2024, NorthView’s stockholders redeemed 0.9% of the total outstanding shares. The aggregate of 18,287,481 public shares redeemed in connection with the Extension represented approximately 75.7% of the total NorthView shares of common stock outstanding following NorthView’s IPO and approximately 96.4% of the public shares previously outstanding. As of September30, 2024, NorthView had 687,519 public shares of NorthView Common Stock outstanding, and held approximately $8.1 million in the Trust Account. x •Profusa, Inc., a California corporation, which we refer to as “Profusa”, is a digital health technology company based in Berkeley, CA, that has developed a real time, consumer -friendlyplatform which measures an individual’s biochemistry, is easy to use, cost -effective, and provides the necessary data to manage chronic disease and health and wellness decisions to improve health outcomes for a large population of potential users. •On November7, 2022, NorthView entered into a Merger Agreement and Plan of Reorganization with Merger Sub and Profusa, which among other things, provides for Merger Sub to be merged with and into Profusa with Profusa being the surviving company and a wholly owned subsidiary of NorthView. •Subject to the terms of the Merger Agreement, the aggregate merger consideration payable to holders of Profusa Common Stock will be equal to the aggregate Per Share Merger Consideration plus the Aggregate Earnout Shares. •NorthView management and the NorthView Board considered various factors in determining whether to approve the Merger Agreement and the Transactions. For more information about the reasons that the NorthView Board considered in determining its recommendation, see “ Proposal 1 — The Business Combination Proposal — The NorthView Board’s Reasons for the Approval of the Business Combination.” When you consider the NorthView Board’s recommendation